Industry and FDA appear aligned on a number of topics in the generic drug user fee renewal negotiations as the clock ticks to complete the negotiations and send the agreement to Congress.
Both sides have reached "tentative, conceptual alignment" on ANDA review goals and program enhancements, drug master file program enhancements and a pre-ANDA process, agency officials told